A study of Eliglustat Tartrate (Genz-112638) in Patients with Gaucher Disease to Evaluate Once Daily versus Twice Daily Dosing

Registry ID

EUCTR2009-015811-42

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Genzyme Europe B.V.

Start date

2010-12-20

Completion date

2015-10-06

Last update

2026-08-16

Conditions

• Gaucher Disease Type I

Summary

The primary objective of this study is to evaluate the efficacy and safety of once daily (QD) versus twice daily (BID) dosing of Genz-112638 in patients with Gaucher disease type 1 who have demonstrated clinical stability on BID dosing of Genz-112638.

Locations

• , , Portugal
• , , Greece
• , , Sweden
• , , Austria

Related clinical trials

• Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease
• A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I

View on source registry